Anastasia Kougioumtzi Panagiotis Ntellas Eirini Papadopoulou George Nasioulas Eleftherios Kampletsas George Pentheroudakis
10.1136/esmoopen-2019-000561
ESMO Open
2019 Oct 25;4(5):e000561.
alk inhibitors alk resistance mutations eml4-alk fusion non-small-cell lung cancer molecular profiling
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/31749991/
Antineoplastic Combined Chemotherapy Protocols / pharmacology Carcinoma, Non-Small-Cell Lung / drug therapy Drug Resistance, Neoplasm / genetics Lung Neoplasms / drug therapy Oncogene Proteins, Fusion / genetics Protein Kinase Inhibitors / pharmacology
Antineoplastic Combined Chemotherapy Protocols / pharmacology Carcinoma, Non-Small-Cell Lung / drug therapy Drug Resistance, Neoplasm / genetics Lung Neoplasms / drug therapy Oncogene Proteins, Fusion / genetics Protein Kinase Inhibitors / pharmacology Case Reports Review Adult Antineoplastic Combined Chemotherapy Protocols / therapeutic use Carcinoma, Non-Small-Cell Lung / genetics Carcinoma, Non-Small-Cell Lung / pathology Disease Progression Fatal Outcome Female Gene Rearrangement Humans Liquid Biopsy Lung Neoplasms / genetics Lung Neoplasms / pathology Oncogene Proteins, Fusion / antagonists & inhibitors Point Mutation Protein Kinase Inhibitors / therapeutic use EML4-ALK fusion protein, human Oncogene Proteins, Fusion Protein Kinase Inhibitors
PMC6830466
31749991
Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
2019